SGLT2 inhibitor effects have been established on cardiomyocytes, endothelial cells, fibroblasts, and smooth muscle cells (Uthman et al., 2018a
Bellinghieri G, Santoro D, Calvani M, Mallamace A, Savica V: Carnitine and hemodialysis
References Abdalla M, Ahmed MA, Cai G, Zarebanadkauki M, Carminati A (2022) Coupled effects of soil drying and salinity on soil-plant hydraulics
2019 Aug 16;11(8):1926
Subcutaneous (SQ) or Intramuscular (IM)
Glucagon-like peptide-1 (GLP-1) receptor agonists are a family of antihyperglycemic drugs that have demonstrated potent HbA1c reduction, low risk of hypoglycemia, with associated weight reduction, and proven cardiovascular and renal benefits.24 In this review we describe this type of drugs, their cardiovascular and renal benefits, as well as their clinical potential in patients with DKD, especially with the new oral semaglutide formulation, now available on the market